(19)
(11) EP 2 460 820 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
19.06.2019 Bulletin 2019/25

(45) Mention of the grant of the patent:
10.04.2019 Bulletin 2019/15

(21) Application number: 12155382.0

(22) Date of filing: 29.12.2005
(51) International Patent Classification (IPC): 
C07K 14/01(2006.01)
C12N 7/04(2006.01)
A61K 39/295(2006.01)
 A61K 39/12(2006.01)
C12Q 1/68(2018.01)

(54)

PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS

IMMUNOGENE PCV2-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR HERSTELLUNG SOLCHER ZUSAMMENSETZUNGEN

COMPOSITIONS IMMUNOGÈNES PCV2 ET PROCÉDÉS DE PRODUCTION DE CES COMPOSITIONS

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
Designated Extension States:
BA HR MK

(30) Priority: 30.12.2004 US 640510 P
13.01.2005 US 34797
29.12.2005 US 319975

(43) Date of publication of application:
06.06.2012 Bulletin 2012/23

(62) Application number of the earlier application in accordance with Art. 76 EPC:
05856068.1 / 1833992

(73) Proprietor: Boehringer Ingelheim Animal Health USA Inc.
Duluth, GA 30096 (US)

(72) Inventors:
  • Eichmeyer, Mark
    St. Joseph, MO 64506-2002 (US)
  • Nitzel, Greg
    St. Joseph, MO 64506-2002 (US)
  • Schaeffer, Merrill
    St. Joseph, MO 64506-2002 (US)

(74) Representative: Hoffmann Eitle 
Patent- und Rechtsanwälte PartmbB Arabellastraße 30
81925 München
81925 München (DE)


(56) References cited: : 
WO-A1-2007/028823
WO-A2-00/77216
 WO-A2-00/01409
WO-A2-2005/009462
   
  • BLANCHARD P ET AL: "Protection of swine against post-weaning multisystemic wasting syndrome (PMWS) by porcine circovirus type 2 (PCV2) proteins", VACCINE, ELSEVIER LTD, GB, vol. 21, no. 31, 7 November 2003 (2003-11-07), pages 4565-4575, XP004467337, ISSN: 0264-410X, DOI: 10.1016/S0264-410X(03)00503-6
  • NAWAGITGUL P ET AL: "Open reading frame 2 of porcine circovirus type 2 encodes a major capsid protein", JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, SPENCERS WOOD, GB, vol. 81, no. 9, 1 January 2000 (2000-01-01), pages 2281-2287, XP002978778, ISSN: 0022-1317
  • KIM YUNA ET AL: "Characterization of the recombinant proteins of porcine circovirus type2 field isolate expressed in the baculovirus system", JOURNAL OF VETERINARY SCIENCE, KOREAN SOCIETY OF VETERINARY SCIENCE, SUWON, KR, vol. 3, no. 1, 1 March 2002 (2002-03-01), pages 19-23, XP002349036, ISSN: 1229-845X
  • KIXMOLLER M ET AL: "Reduction of PMWS-associated clinical signs and co-infections by vaccination against PCV2", VACCINE, ELSEVIER LTD, GB, vol. 26, no. 27-28, 25 June 2008 (2008-06-25), pages 3443-3451, XP022710551, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2008.04.032 [retrieved on 2008-05-05]
  • FACHINGER ET AL: "The effect of vaccination against porcine circovirus type 2 in pigs suffering from porcine respiratory disease complex", VACCINE, ELSEVIER LTD, GB, vol. 26, no. 11, 1 March 2008 (2008-03-01) , pages 1488-1499, XP022505432, ISSN: 0264-410X
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).